Literature DB >> 3358894

The effect of ageing on the disposition of nifedipine and atenolol.

M Scott1, C M Castleden, H K Adam, R P Smith, T J Fitzsimons.   

Abstract

1. Healthy young and elderly volunteers received 20 mg nifedipine (slow release) orally for 2 weeks with concomitant dosing of atenolol 50 mg orally during the second week. 2. Drug kinetics and dynamics were compared between the groups after a single dose of nifedipine (day 1), after chronic dosing for 1 week (day 8), and following concomitant daily dosing of atenolol (day 15). 3. Plasma profiles of nifedipine were similar within each group on each of the 3 sampling days. The elderly group had higher plasma concentrations from about 6 h but there was no difference in the maximum concentrations achieved. The half-life in the elderly was significantly longer (8.8 +/- 0.9 h) compared with that in the young (5.8 +/- 1.1 h) (P less than 0.01). 4. Blood concentrations of atenolol were higher in the elderly at 12 and 24 h post-dose (P less than 0.001) and the AUC was greater than in the young (P less than 0.001). 5. Systolic blood pressure was reduced by nifedipine in both groups but to a greater extent in the elderly (P less than 0.01); differences in diastolic blood pressure were not significant. Blood pressure was reduced further by the addition of atenolol. Atenolol reduced the heart rate in all subjects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3358894      PMCID: PMC1386352          DOI: 10.1111/j.1365-2125.1988.tb03306.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  Clinical pharmacokinetics of atenolol.

Authors:  J McAinsh
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

2.  Reduced beta-adrenoceptor sensitivity in the elderly.

Authors:  R E Vestal; A J Wood; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1979-08       Impact factor: 6.875

3.  Gas chromatographic determination of nifedipine and one of its metabolites using electron capture detection.

Authors:  P Jakobsen; O Lederballe Pedersen; E Mikkelsen
Journal:  J Chromatogr       Date:  1979-01-01

4.  Kinetics and absolute bioavailability of atenolol.

Authors:  W D Mason; N Winer; G Kochak; I Cohen; R Bell
Journal:  Clin Pharmacol Ther       Date:  1979-04       Impact factor: 6.875

5.  Acute and chronic effects of nifedipine in arterial hypertension.

Authors:  O L Pedersen; E Mikkelsen
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

6.  Aging, total body potassium, fat-free mass, and cell mass in males and females between ages 18 and 85 years.

Authors:  L P Novak
Journal:  J Gerontol       Date:  1972-10

7.  Pharmacokinetics of atenolol in patients with renal impairment.

Authors:  J Sassard; N Pozet; J McAinsh; J Legheand; P Zech
Journal:  Eur J Clin Pharmacol       Date:  1977-11-14       Impact factor: 2.953

8.  The gas chromatographic determination of atenolol in biological samples.

Authors:  B Scales; P B Copsey
Journal:  J Pharm Pharmacol       Date:  1975-06       Impact factor: 3.765

9.  Digoxin in the elderly: pharmacokinetic consequences of old age.

Authors:  B Cusack; J Kelly; K O'Malley; J Noel; J Lavan; J Horgan
Journal:  Clin Pharmacol Ther       Date:  1979-06       Impact factor: 6.875

10.  Pharmacokinetics, pharmacology of atenolol and effect of renal disease.

Authors:  S H Wan; R T Koda; R F Maronde
Journal:  Br J Clin Pharmacol       Date:  1979-06       Impact factor: 4.335

View more
  14 in total

Review 1.  Cardiovascular drug therapy in elderly patients: specific age-related pharmacokinetic, pharmacodynamic and therapeutic considerations.

Authors:  Arduino A Mangoni
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

2.  Steady state pharmacokinetics of hydrolysed bopindolol in young and elderly men.

Authors:  D Holmes; E Nuesch; J M Houle; J Rosenthaler
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

Review 4.  Calcium channel antagonists: Part VI: Clinical pharmacokinetics of first and second-generation agents.

Authors:  L H Opie
Journal:  Cardiovasc Drugs Ther       Date:  1989-08       Impact factor: 3.727

5.  Age and sex-related differences in dose-dependent hemodynamic response to landiolol hydrochloride during general anesthesia.

Authors:  Ju Mizuno; Ikuto Yoshiya; Takeshi Yokoyama; Yoshitsugu Yamada; Hideko Arita; Kazuo Hanaoka
Journal:  Eur J Clin Pharmacol       Date:  2007-01-09       Impact factor: 2.953

6.  Misuse of the standard error of the mean.

Authors:  A Herxheimer
Journal:  Br J Clin Pharmacol       Date:  1988-08       Impact factor: 4.335

Review 7.  Antihypertensive therapy in the aged patient. Clinical pharmacokinetic considerations.

Authors:  R W Piepho; K J Fendler
Journal:  Drugs Aging       Date:  1991-05       Impact factor: 3.923

Review 8.  Calcium antagonists in the elderly. A risk-benefit analysis.

Authors:  J B Schwartz
Journal:  Drugs Aging       Date:  1996-07       Impact factor: 3.923

Review 9.  The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties.

Authors:  J S Grundy; R T Foster
Journal:  Clin Pharmacokinet       Date:  1996-01       Impact factor: 6.447

Review 10.  Adverse drug reactions. An overview of special considerations in the management of the elderly patient.

Authors:  L A Brawn; C M Castleden
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.